Atmospheric Neutron Monitoring through Optical Fiber-Based Sensing.

The potential of fiber-based sensors to monitor the fluence of atmospheric neutrons is evaluated through accelerated tests at the TRIUMF Neutron Facility (TNF) (BC, Canada), offering a flux approximatively 109 higher than the reference spectrum observed under standard conditions in New York City, USA. The radiation-induced attenuation (RIA) at 1625 nm of a phosphorus-doped radiation sensitive optical fiber is shown to linearly increase with neutron fluence, allowing an in situ and easy monitoring of the neutron flux and fluence at this facility. Furthermore, our experiments show that the fiber response remains sensitive to the ionization processes, at least up to a fluence of 7.1 × 1011 n cm-², as its radiation sensitivity coefficient (~3.36 dB km-1 Gy-1) under neutron exposure remains very similar to the one measured under X-rays (~3.8 dB km-1 Gy-1) at the same wavelength. The presented results open the way to the development of a point-like or even a distributed dosimeter for natural or man-made neutron-rich environments. The feasibility to measure the dose caused by the neutron exposure during stratospheric balloon experiments, or during outer space missions, is presented as a case study of a potential future application.

Outcomes of proton radiation therapy for peripapillary choroidal melanoma at the BC Cancer Agency.

PURPOSE: To report toxicity, local control, enucleation, and survival rates for patients with peripapillary choroidal melanoma treated with proton therapy in Canada. METHODS AND MATERIALS: We performed a retrospective analysis of patients with peripapillary choroidal melanoma (≤ 2 mm from optic disc) treated between 1995 and 2007 at the only Canadian proton therapy facility. A prospective database was updated for follow-up information from a chart review. Descriptive and actuarial data are presented. RESULTS: In total, 59 patients were treated. The median age was 59 years. According to the 2010 American Joint Committee on Cancer TNM classification, there were 20 T1 tumors (34%), 28 T2 tumors (48%), and 11 T3 tumors (19%). The median tumor diameter was 11.4 mm, and the median thickness was 3.5 mm. Median follow-up was 63 months. Nineteen patients received 54 cobalt gray equivalents (CGE) and forty patients received 60 CGE, each in 4 fractions. The 5-year actuarial local control rate was 91% (T1, 100%; T2, 93%; and T3, 59%) (p = 0.038). There was a suggestive relationship between local control and dose. The local control rate was 97% with 60 CGE and 83% with 54 CGE (p = 0.106). The metastasis-free survival rate was 82% and related to T stage (T1, 94%; T2, 84%; and T3, 47%) (p < 0.001). Twelve patients died, including eleven with metastases. The 5-year actuarial rate of neovascular glaucoma was 31% (23% for T1-T2 and 68% for T3, p < 0.001), and that of enucleation was 0% for T1, 14% for T2, and 72% for T3 (p < 0.001). Radiation retinopathy (74%) and optic neuropathy (64%) were common within-field effects. CONCLUSIONS: Proton therapy provides excellent local control with acceptable toxicity while conserving the globe in 80% of cases. These results are consistent with other single-institution series using proton radiotherapy, and toxicity rates were acceptable. T3 tumors carry a higher rate of both local recurrence and metastasis.

The biological effectiveness of antiproton irradiation.

BACKGROUND AND PURPOSE: Antiprotons travel through tissue in a manner similar to that for protons until they reach the end of their range where they annihilate and deposit additional energy. This makes them potentially interesting for radiotherapy. The aim of this study was to conduct the first ever measurements of the biological effectiveness of antiprotons. MATERIALS AND METHODS: V79 cells were suspended in a semi-solid matrix and irradiated with 46.7MeV antiprotons, 48MeV protons, or (60)Co gamma-rays. Clonogenic survival was determined as a function of depth along the particle beams. Dose and particle fluence response relationships were constructed from data in the plateau and Bragg peak regions of the beams and used to assess the biological effectiveness. RESULTS: Due to uncertainties in antiproton dosimetry we defined a new term, called the biologically effective dose ratio (BEDR), which compares the response in a minimally spread out Bragg peak (SOBP) to that in the plateau as a function of particle fluence. This value was approximately 3.75 times larger for antiprotons than for protons. This increase arises due to the increased dose deposited in the Bragg peak by annihilation and because this dose has a higher relative biological effectiveness (RBE). CONCLUSION: We have produced the first measurements of the biological consequences of antiproton irradiation. These data substantiate theoretical predictions of the biological effects of antiproton annihilation within the Bragg peak, and suggest antiprotons warrant further investigation.